6058-57-7

Basic information

• Product Name: 1-(2-BROMO-ETHYL)-2-METHYL-5-NITRO-1H-IMIDAZOLE
• Synonyms: 1-(2-BROMO-ETHYL)-2-METHYL-5-NITRO-1H-IMIDAZOLE;1-(2-Bromoethyl)-2-methyl-5-nitroimidazole
• CAS NO: 6058-57-7
• Molecular Formula: C₆H₈BrN₃O₂
• Molecular Weight: 234.05062
• Mol File: 6058-57-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 81.2 °C(Solv: ethyl ether (60-29-7))
• Boiling Point: 379.4 °C at 760 mmHg
• Flash Point: 183.3 °C
• Appearance: /
• Density: 1.75 g/cm³
• Vapor Pressure: 1.28E-05mmHg at 25°C
• Refractive Index: 1.635
• PKA: 2.38±0.34(Predicted)
• CAS DataBase Reference: 1-(2-BROMO-ETHYL)-2-METHYL-5-NITRO-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BROMO-ETHYL)-2-METHYL-5-NITRO-1H-IMIDAZOLE(6058-57-7)
• EPA Substance Registry System: 1-(2-BROMO-ETHYL)-2-METHYL-5-NITRO-1H-IMIDAZOLE(6058-57-7)

Safety Data

• Hazardous Substances Data: 6058-57-7(Hazardous Substances Data)

Usage

General Description

1-(2-Bromo-ethyl)-2-methyl-5-nitro-1H-imidazole is a chemical compound with the molecular formula C7H8BrN3O2. It is a derivative of imidazole, a five-membered heterocyclic ring with two non-adjacent nitrogen atoms. The presence of a bromo-ethyl group and a nitro group in the compound gives it potential applications as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound may also have antimicrobial properties due to the presence of the nitro group, which is known to exhibit antimicrobial activity in various organic compounds. However, caution should be exercised when handling this compound, as bromo-ethyl and nitro groups are known to be toxic or harmful to humans and the environment.

InChI:InChI=1/C6H8BrN3O2/c1-5-8-4-6(10(11)12)9(5)3-2-7/h4H,2-3H2,1H3

Upstream product

• 30575-42-9 toluene-4-sulfonic acid 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl ester 
• 443-48-1 metronidazole 
• 696-23-1 2-methyl-5-nitro-1H-imidazole 
• 106-93-4 ethylene dibromide 
• 696-23-1 2-methyl-4-nitro-1H-imidazole 
• 30746-54-4 2-(5-nitro-2-methyl-1-imidazolyl)ethyl methanesulfonate 

Downstream Products

• 1175005-77-2 1-(2-fluorophenyl)-4-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)piperazine 
• 1214889-78-7 N-[3-(3-fluoro-4-{4-[2-(2-methyl-5-nitro-imidazol-1-yl)-ethyl]-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 
• 60666-28-6 [2-(2-methyl-5-nitro-1H-imidazol-1-yl)]ethylazide 
• 64757-26-2 1-(2-thiocyanoethyl)-2-methyl-5-nitroimidazole 
• 1260218-09-4 4-(5-((2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazol-2-yl)aniline 
• 1260218-08-3 2-(5-((2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazol-2-yl)aniline 
• 1260218-05-0 2-(4-Methoxyphenyl)-5-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazole 
• 1260218-03-8 2-(2-Methoxyphenyl)-5-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazole 
• 1260218-02-7 2-((2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-5-(p-tolyl)-1,3,4-oxadiazole 
• 1260218-01-6 2-((2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-5-(o-tolyl)-1,3,4-oxadiazole 
• 1260218-00-5 2-((2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-5-phenyl-1,3,4-oxadiazole 
• 1429183-47-0 2-((2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole 
• 1429183-46-9 2-(3,5-Dimethoxyphenyl)-5-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazole 
• 1429183-45-8 5-Methoxy-2-(5-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazol-2-yl)phenol 

Relevant articles and documents

Synthesis of novel hybrid molecules from precursors with known antiparasitic activity

Three novel new compounds derived from antiparasitic precursors have been synthesized and tested for their antiamoebic and antigiardial activities. The condensation of 2-(2-methyl-5-1H-nitroimidazolyl)ethylamine (6) with 5-nitro-2-furylacrylic acid (7) gave 3-(5-nitrofuran-2-yl)-N-[2-(5- nitroimidazol-1-yl)ethyl]acrylamide (8). Condensation of 7 with 7-chloro-4-(piperazin-1-yl)quinoline (9) afforded 1-[4-(7-chloroquinolin-4-yl) piperazin-1-yl)-3-(5-nitrofuran-2-yl)propenone as a mixture of two isomers; 10-a (the E-isomer) and 10-b (the Z-isomer). In addition, the reaction of 9 with 1-(2-bromoethyl)-2-methyl-5-nitroimidazole (11) in the presence of K 2CO3 and NaI yielded 7-chloro-4-(4-[2-(5-nitroimidazol-1- yl)ethyl]-piprazin-1-yl)quinoline (12). On the basis of preliminary screening data for these new compounds, compound 12 exhibited potent lethal activities against Entamoeba histolytica and Giardia intestinalis; its IC50 ( about 1 μM) was lower, at least by a factor of five, compared to the standard drug, metronidazole. In addition, the IC50 of compound 12 against the tested parasites is 600 times below that against Hep-2 and Vero cells. Compounds 8 and 10-a also exhibited potent or moderate antiamoebic and antigiardial activities with IC50 values of about 5.5 μM, and 140 μM, respectively, against the tested parasites. These two hybrid molecules, 8, 10-a, were also non-cytotoxic at the lethal concentrations against the parasites.

Crystal Habit Modification of Metronidazole by Supramolecular Gels with Complementary Functionality

A series of bis(urea) compounds with complementary functional groups similar to the pharmaceutical drug metronidazole and a structural isomer isometronidazole have been synthesized. The gelation properties of these compounds were studied in various solvent/solvent mixtures. The mechanical strength of the isomeric gelators was compared using rheology, and the morphologies of the xerogels were analyzed by scanning electron microscopy. These gels were used as media for metronidazole crystallization resulting in a marked habit modification of the metronidazole crystals in the drug-mimicking gels. However, crystallization in the nonmimetic isomeric gel resulted in morphologies similar to the solution state. These results indicate that the drug-mimetic gels interact with the surface of the drug crystal giving rise to new morphologies.

A treating agent temp.and for water treatment and preparation method thereof

The invention relates to a biological slime treating agent for water treatment and a preparation method of the biological slime treating agent. The biological slime treating agent comprises the following components in percentage by weight: 5-30% of 1-(2-thiocyano)ethyl-2-methyl-3-benzyl-5-nitroimidazole, 5-10% of N,N-bis(dodecyldimethyl)-3-oxa-1,5-pentadiammonium dichloride, 5-10% of dithiocyanomethane, 1-10% of isothiazolinone, 1-10% of organochlorine, 5-40% of a solvent and the balance of water. The preparation method of the biological slime treating agent is as follows: at room temperature, adding 1-(2-thiocyano)ethyl-2-methyl-3-benzyl-5-nitroimidazole, N,N-bis(dodecyldimethyl)-3-oxa-1,5-pentadiammonium dichloride and water into a reactor, adjusting the pH value to less than 6 with hydrochloric acid, adding an alcohol solvent, uniformly stirring, adding isothiazolinone and organochlorine and stirring until isothiazolinone and organochlorine are completely dissolved to obtain the biological slime treating agent. The biological slime treating agent has good bactericidal property, can be widely used in industrial circulating water treatment and especially can be suitable for controlling the breeding of bacteria such as SRB in an oily wastewater system of an oilfield.

Synthesis of nitroimidazole derived oxazolidinones as antibacterial agents

A series of N-alkylated derivatives of nitroimidazolyl oxazolidinones 6a-i with various substituent at N-1 position of the nitroimidazole were synthesized and their in-vitro antibacterial activities were evaluated against several Gram-positive and Gram-ne